Pronunciation: yoo-fly’-mah Generic name: adalimumab-aaty Dosage forms: Yuflyma Auto-injector (40 mg/0.4mL), Yuflyma Prefilled Syringe with Safety Guard Injection (40 mg/0.4 mL), ... show all 3 dosage forms Drug class: TNF alfa inhibitors...
Celltrion USA announced the launch of Yuflyma® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, providing an alternative option for patients. Yuflyma is indicated for the treatment of eight conditions, including ...
Yuflyma (Adalimumab-aaty) is the fifth biosimilar of Humira and the second anti-TNF antagonist developed by Celltrion Healthcare to receive FDA approval. Yuflyma offers patients a high-concentration (40 mg/ 0.4 ml in a prefilled syringe with auto-injector) and citrate-free formulation of ...
CelltrionUSA has received approval from the US Food and Drug Administration (FDA) forHumira (adalimumab) biosimilar, Yuflyma (adalimumab-aaty), for multiple indications. Yuflyma is indicated to treat juvenile idiopathic arthritis, hidradenitis suppurativa, Crohn’s disease, plaque psoriasis, ankylosing...